Dynamic Technology Lab Private Ltd purchased a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,740 shares of the company's stock, valued at approximately $420,000.
Several other institutional investors have also made changes to their positions in the stock. Lord Abbett & CO. LLC purchased a new stake in shares of Guardant Health during the 3rd quarter worth about $15,624,000. Guyasuta Investment Advisors Inc. bought a new stake in Guardant Health in the fourth quarter worth approximately $206,000. Geode Capital Management LLC increased its stake in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Entropy Technologies LP bought a new position in shares of Guardant Health during the 4th quarter valued at $377,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Guardant Health in the 4th quarter valued at $2,211,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Guardant Health Price Performance
Shares of GH traded up $1.70 during mid-day trading on Monday, reaching $45.41. The company had a trading volume of 294,648 shares, compared to its average volume of 2,135,707. The company has a market capitalization of $5.60 billion, a P/E ratio of -12.76 and a beta of 1.45. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89. The company's 50-day moving average is $43.57 and its 200-day moving average is $35.78.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
GH has been the topic of several recent research reports. JPMorgan Chase & Co. raised their target price on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Guggenheim restated a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Barclays decreased their target price on Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Thursday. Scotiabank boosted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Finally, The Goldman Sachs Group raised their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $49.00.
Check Out Our Latest Stock Analysis on GH
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Read More
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
